Abeona Therapeutics Inc(ABEO) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -1.12 | Insider Own | 11.33% | Shs Outstand | 57.2M | Perf Week | 2.01% |
| Market Cap | 0.26B | Forward P/E | - | EPS next Y | 80.95% | Insider Trans | -5.38% | Shs Float | 50.7M | Perf Month | -13.14% |
| Enterprise Value | 0.13B | PEG | - | EPS next Q | -0.17 | Inst Own | 69.15% | Short Float | 33.95% | Perf Quarter | -28.97% |
| Income | -0.06B | P/S | 10.22 | EPS this Y | -195.79% | Inst Trans | 1.01% | Short Ratio | 12.72 | Perf Half Y | -16.48% |
| Sales | 0.03B | P/B | 2.04 | EPS next 5Y | -27.34% | ROA | -29.54% | Short Interest | 17.21M | Perf YTD | -13.47% |
| Book/sh | 2.24 | P/C | 1.78 | EPS past 3/5Y | - | ROE | -43.13% | 52W High | -40.39% ($7.65) | Perf Year | -8.62% |
| Cash/sh | 2.57 | P/FCF | - | Sales past 3/5Y | 60.26% -10.26% | ROIC | -47.17% | 52W Low | 14% ($4.00) | Perf 3Y | 22.91% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -212.54% | Gross Margin | 47.17% | Volatility(W/M) | 3.86% 4.53% | Perf 5Y | -77.55% |
| Dividend TTM | - | EV/Sales | 5.24 | Sales Y/Y TTM | 6280% | Oper. Margin | -327.64% | ATR (14) | 0.22 | Perf 10Y | -97.41% |
| Dividend Ex-Date | - | Quick Ratio | 6.4 | EPS Q/Q | -120.75% | Profit Margin | -246.42% | RSI (14) | 41.23 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 6.63 | Sales Q/Q | 2745% | SMA20 | -2.2% ($4.66) | Beta | 1.47 | Target Price | $18.88 |
| Payout | - | Debt/Eq | 0.16 | Earnings | 2026/8/13 | SMA50 | -13.56% ($5.28) | Rel Volume | 0.65 | Prev Close | $4.55 |
| Employees | 226 | LT Debt/Eq | 0.04 | EPS/Sales Surpr. | -51.06% -7.01% | SMA200 | -17.05% ($5.5) | Avg Volume(3M) | 1.35M | Price | $4.56 |
| IPO | 1980/9/19 | Option/Short | Yes/Yes | Trades | 2373 | Volume | 874,347 | Change | 0.22% |
🧬 This is a US biotech company developing gene and cell therapies targeting rare genetic diseases. The company develops autologous cell-based gene therapies in rare disease areas, including severe inherited skin disorders, and is positioning itself as an integrated clinical-commercial biotech that has entered the early commercialization stage.
Over the past 1 year, on the lower side
40% below its 1-year high.
Traded less than usual. That is 65% of its average volume.
ABEO has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -195.8% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $1,022. Peers typically go for $1,217. Compared with its own 1-year average, it is 13% cheaper now.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -77.5%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Short interest is a burden
34.0% of the float is sold short.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #277 of 594 in the industry
Based on market cap of $261M.
ABEO#277 Abeona Therapeutics Inc $261M PER - 
LCTX#278 Lineage Cell Therapeutics Inc $260M PER - 
IMRX#279 Immuneering Corp $260M PER - 
CUVL#280 Clinuvel Pharmaceuticals Ltd ADR $260M PER 11.2 
FATE#281 Fate Therapeutics Inc $260M PER - 
FAQ
What kind of company is ABEO?
ABEO belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of ABEO?
The market cap of ABEO is approximately $261M, ranking 3,804 within its sector.
What is the 52-week high and low for ABEO?
ABEO has recorded a 52-week high of $7.65 and a low of $4.00.
